Cell infusions (intravenous or direct injection) are minimally invasive and cause few acute side effects; patients typically leave the same day. Biochemical changes in bone remodelling unfold over weeks to months, so meaningful clinical assessment requires 3–6 months minimum, with optimal evaluation at 12–18 months.
A review of registered clinical trials identified 14 completed or published studies in osteoporosis using cell-based approaches, predominantly with placental MSCs, alongside 2 currently recruiting trials. Trial sizes have ranged from 20 to 120 participants. Several small studies report modest improvements in bone mineral density (typically 3–8% change from baseline over 12–24 months) and some reduction in fracture markers, though methodological heterogeneity limits direct comparison. No large, multi-centre, phase III efficacy trial has yet reported.
Suis-je un candidat? → · Osteoporosis & Bone Health: full overview → · Coût Ostéoporose et Santé Osseuse → · Cost →
Médicalement examiné par l'équipe éditoriale de StemCellAtlas avec Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) de la clinique partenaire Stem Plus (Sofia), selon les directives ISSCR, FDA et EMA. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite